role of ropivacaine as pain relief on patients undergoing split thickness skin grafting of lower limb, at donor site

To evaluate the effect of 0.2% ropivacaine moistened V/S normal saline moistened dressings on post operative pain relief in patients undergoing lower limb split thickness skin grafting (SSG) at donor site: A prospective randomised double blind placebo study.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/018079

Enrollment

100

Registered

2019-03-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: V00-Y99- External causes of morbidity Health Condition 2: null- Patient having skin defect or contracture of lower limb

Interventions

Intervention1: Injection Ropivacaine: 0.2% , 12ml/10cm sq area of ssg donor site Control Intervention1: Ropivacaine 0.2%: 0.2% Ropivacaine moistened dressing Control Intervention2: Normal saline: Norm

Eligibility

Inclusion criteria

Inclusion criteria: Patients who will undergo elective split thickness skin grafting for reconstruction of various defects of lower limb, in whom thigh will be used as SSG donor site

Exclusion criteria

Exclusion criteria: Patient refusal, Age <16 years, Coagulopathy, ASA Grade III & IV, History of allergy, Local infection at the site of block, Pregnant women, Immunocompromised patients,Apprehensive/ Psychiatric patients.

Design outcomes

Primary

Measure	Time frame
Duration of analgesiaTimepoint: Within 24 hours	—

Secondary

Measure	Time frame
Need of rescue analgesiaTimepoint: Within 24 hours	—

Countries

India

Contacts

Public ContactDr Ajay Kumar Jain

RNT Medical College Udaipur

drlalitkumar@hotmail.com9414352823

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026